Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT02193295 Sponsor: Yale University Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT02193295
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are healthy, not physically active on a regular basis, non-smoking, and not taking any medications except possibly birth control pills.
  • People whose hematocrit (a measure of red blood cells in the blood) is above 35%.
  • People with no whole-body or organ-related diseases, including no diabetes.
  • People with no history of eating disorders.
  • Women must be using a form of birth control (such as abstinence, birth control pills, Norplant, an IUD, or condoms) and, unless on birth control pills or having had a hysterectomy, must be tested between days 0 and 7 of their menstrual cycle.
  • Women who take birth control pills or have had a hysterectomy may be studied at any point in their cycle.
  • People whose physical activity level falls below a set threshold, as measured by a standard activity questionnaire (confirm with trial site for exact scoring details).

Who may not be able to join:

  • People who do not meet the inclusion criteria listed above, including those with a history of eating disorders or any whole-body or organ disease, including diabetes.
  • People with lactose intolerance.
  • People with any abnormalities in blood count or blood clotting.
  • People with high triglyceride levels (above 100 mg/dL in blood).
  • People whose hematocrit is below 35%.
  • Women of childbearing age who are not using contraception or who are not abstinent.
  • People who follow a regular exercise routine.
  • People with metal implants or body piercings that cannot be removed before MRI scans.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kitt Petersen, MD, Yale University

Phone: 203-785-5447

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
1 October 2002
Est. completion
1 October 2034

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Improvements in insulin sensitivity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov